Skip to main content

Clonorchiasis

3
Pipeline Programs
1
Companies
1
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
3
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
1100%
+ 2 programs with unclassified modality

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Autonomous Therapeutics
3 programs
3
AlbendazolePhase 4Small Molecule1 trial
PraziquantelPhase 4
TribendimidinePhase 4
Active Trials
NCT07074444Recruiting318Est. Dec 2026

Trial Timeline

Clinical trial activity over time

2025
2026
Autonomous TherapeuticsAlbendazole

Clinical Trials (1)

Total enrollment: 318 patients across 1 trials

Treatment of Clonorchiasis in Guangxi With Albendazole, Tribendimidine, and Praziquantel

Start: Jul 2025Est. completion: Dec 2026318 patients
Phase 4Recruiting

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 actively recruiting trials targeting 318 patients
1 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.